Ancora Advisors’s Orchestra BioMed OBIO Stock Holding History

Ancora Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,400	Closed	-$54K	–	2483
2021 Q4	$54K	Hold	5,400	–	–	﹤0.01%	1228
2021 Q3	$53K	Buy	+5,400	New	+$53.3K	﹤0.01%	1170

Other funds holding OBIO

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ancora Advisors's OBIO Position: Q1 2022 in Review

Ancora Advisors sold out of Orchestra BioMed (OBIO) in Q1 2022, closing a stake of 5,400 shares — an estimated $54K sold.

Ancora Advisors first reported a position in OBIO in Q3 2021 and held it in 2 quarters. The position peaked at $54K in Q4 2021. 59 funds tracked by Wall St. Rank hold OBIO as of Q1 2022.

Ancora Advisors reported no remaining Orchestra BioMed position as of Q1 2022 after selling out during the quarter.
Ancora Advisors sold 5,400 Orchestra BioMed shares in Q1 2022, an estimated $54K.
Ancora Advisors first reported a position in Orchestra BioMed in Q3 2021 and held it in 2 quarters.
Ancora Advisors's Orchestra BioMed position peaked at $54K in Q4 2021.
59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2022.

Based on Ancora Advisors's 13F filing for Q1 2022, filed 13 May 2022.